… is only effective as combination treatment with inhibitors of other nodes of the RAS-ERK …
adaptive resistance after prolonged treatment in vitro with the allosteric SHP2 inhibitor SHP099. …

… Since SHP2 is considered as a novel antitumor target, we also summarized currently used
SHP2 inhibitors … of adaptive resistance, whereas SHP2 inhibitor SHP099 combined with MEK …

… A genome-wide CRISPR screen has identified that loss of INPPL1, MAP4K5, or LZTR1
genes results in resistance to SHP2 inhibition in vitro and in vivo by MAPK reactivation (123), as …

… ON) inhibitor, RM-029, which targets the GTP-bound active state, with the SHP2 inhibitor
RMC-… tumor microenvironment (TME) which can lead to adaptive anti-tumor immune responses. …

… Given the roles of SHP2 in growth factor receptor-mediated signaling pathways, the …
EGFR/SHP2 inhibitors may also be an effective strategy for treating adaptive resistance cancers. …

… AXL as a therapeutic target, we hypothesized that inhibiting SHP2, a signaling node directly
… TKI to combat against adaptive resistance. Using the allosteric SHP2 inhibitor SHP099, we …

… SHP2 inhibition is also being evaluated for its ability to block adaptive resistance to other …
role in combination with MAPK inhibition, we hypothesize that SHP2 inhibition may serve as a …

… and resistance to MEKi in DTC, which is reversed by SHP2 blockade. As a novel active inhibitor
of SHP2… is a promising therapeutic approach for advanced DTC and MEKi-resistant one. …

… PI3K inhibition circumvents SHP2i resistance but, given the pleiotropic activity of SHP2,
additional mechanisms of resistance … It has been reported for example that resistance to SHP099 …

… resistance to both catalytic and allosteric SHP2 inhibitors. … receptor (EGFR) drug resistance
in both lung and colorectal … the resistance of KRAS Q61H mutant cells to SHP2 inhibitors …